Neuren Pharmaceuticals Limited
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NEU.AX | ACAD | NGNE | B9A.F | 1875.HK | TVTX | |
|---|---|---|---|---|---|---|
| Market cap | 2.95B | 3.70B | 551.91M | 2.45B | 2.56B | 5.03B |
| P/E (TTM) | 154.9 | 9.6 | — | 250.7 | — | — |
| Forward P/E | 38.9 | 23.3 | -4.8 | — | 42.9 | 9.9 |
| Price/book | 8.8 | 3.0 | 2.0 | 1.2 | 3.8 | 222.1 |
| Dividend yield | 1.52% | — | — | 0.68% | — | — |
| 1-year change | −2.22% | −7.88% | −3.79% | +5.23% | +69.54% | +46.53% |
| Today | +17.49% | +4.38% | +3.41% | −0.29% | +5.54% | +6.09% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All NEU.AX news ›Neuren Pharmaceuticals: Spending More to Grow Beyond DAYBUE
Drug development is a game of patience. Investors are already wondering where the next wave of growth will come from. Published on 10/21/2026 at 05:03 am EDT - Modified on 10/21/2026 at 07:55 am EDT Australia’s newest blueprint for the…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.